nach oben

Erschienen in:

2019 | OriginalPaper | Buchkapitel

23. Großzellige und aggressive B-Zell Lymphome

verfasst von : Prof. Dr. Andreas Rosenwald, Prof. Dr. Martina Rudelius

Erschienen in: Pathologie

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Diffuse großzellige B-Zell Lymphome (DLBCL) sind seit ihrer ursprünglichen Klassifikation als heterogene Gruppe mehrerer Entitäten definiert worden. Seither wurden nach morphologischen, klinischen und molekularen Kriterien in der WHO Klassifikation verschiedene Entitäten abgegrenzt und auch in der Gruppe der nach Entitäten nicht weiter unterscheidbaren Formen des Lymphknotenbefalls unterschiedliche molekulare Ableitungen von Keimzentrumszellen oder aktivierten B-Zellen definiert. In diesem Kapitel sind alle Entitäten des DLBCL mit primärem Lymphknotenbefall, die Burkitt Lymphome, sowie Varianten mit intermediären morphologischen oder molekulargenetischen Befunden und nicht organtypische Entitäten der DLBCL behandelt und in ihrer Abgrenzung dargestellt, sodass eine klinisch und therapeutisch relevante Differenzialdiagnose ermöglicht wird.

Alizadeh AA, Eisen MB, Davies RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, Tran T, Yu X, Powell JJ, Yang L, Marti GE, Moore T, Hudson J, Lu L, Lewis DB, TibshiraniR, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JEO, Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botsetin D, Brown PO, Staudt LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503–511CrossRefPubMed

Anon (1997) A clinical evaluation of the international Lymphoma Study Group classification of non-Hodgkin´s lymphoma. The Non-Hodgkin´s lymphoma classification project. Blood 89:3309–3918

Aukema SM, Kreuz M, Kohler CW, Rosolowski M, Hasenclever D, Hummel M, Küppers R, Lenze D, Ott G, Pott C, Richter J, Rosenwald A, Szczepanowski M, Schwaenen C, Stein H, Trautmann H, Wessendorf S, Trümper L, Loeffler M, Spang R, Kluin PM, Klapper W, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network Project (2014) Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica 99:726–735CrossRefPubMedPubMedCentral

Bogusz AM, Seegmiller AC, Garcia R, Shang P, Ashfaq R, Chen W (2009) Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Pathol 132:597–605CrossRefPubMed

Brune V, Tiacci E, Pfeil I, Doring C, Eckerle S, van Noesel CJ, Klapper W, Falini B, von Heydebreck A, Metzler D, Brauninger A, Hansmann ML, Kuppers R (2008) Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med 205:2251–2268CrossRefPubMedPubMedCentral

Burkitt D (1958) A sarcoma involving the jaws in African children. Br J Surg 46:218–223CrossRefPubMed

Castillo JJ, Bibas M, Miranda RN (2015) The biology and treatment of plasmablastic lymphoma. Blood 125(15):2323–2330CrossRefPubMed

Chadburn A, Hyjek E, Mathew S, Cesarman E, Said J, Knowles DM (2004) KSHV-positive solid lymphomas represent an extra-cavitary variant of primary effusion lymphoma. Am J Surg Pathol 28:1401–1416CrossRefPubMed

Cohen M, Narbaitz M, Metrebian F, de Matteo E, Preciado MV, Chabay BA (2014) Epstein-Barr virus-positive diffuse large B-cell lymphoma association is not only restricted to elderly patients. Int J Cancer 135:2816–2824CrossRefPubMed

10.

Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM (1982) Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A 79:7824–7827CrossRefPubMedPubMedCentral

11.

Dave SS, Fu K, Wright GW, Lam LT, Kluin P, Boerma EJ, Greiner TC, Weisenburger DD, Rosenwald A, Ott G, Müller-Hermelink HK, Gascoyne RD, Delabie J, Rimsza LM, Braziel RM, Grogan TM, Campo E, Jaffe ES, Dave BJ, Sanger W, Bast M, Vose JM, Armitage JO, Connors JM, Smeland EB, Kvaloy S, Holte H, Fisher RI, Miller TP, Montserrat E, Wilson WH, Bahl M, Zhao H, Yang L, Powell J, Simon R, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project (2006) Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med 354:2431–2442CrossRefPubMed

12.

Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, Jiang JK, Thomas CJ, Rosenwald A, Ott G, Muller-Hermelink HK, Gascoyne RD, Connors JM, Johnson NA, Rimsza LM, Campo E, Jaffe ES, Wilson WH, Delabie J, Smeland EB, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pierce SK, Staudt LM (2010) Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 463:88–92CrossRefPubMedPubMedCentral

13.

Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, Huhn D, Schmidt-Westhausen A, Reichart PA, Gross U, Stein H (1997) Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 89:1413–1420PubMed

14.

Delsol G, Lamant L, Mariame B, Pulford K, Dastugue N, Brousset P, Rigal-Huguet F, al Saati T, Cerretti DP, Morris SW, Mason DY (1997) A new subtype of large B-cell lymphoma expressing the ALK kinase and lacking the 2;5 translocation. Blood 89:1483–1490PubMed

15.

De Paepe P, Baens M, van Krieken H, Verhasselt B, Stul M, Simons A, Poppe B, Laureys G, Brons P, Vandenberghe P, Speleman F, Praet M, Wolf-Peeters C, Marynen P, Wlodarska I (2003) ALK activation by the CLTC-ALK fusion is a recurrent event in large B-cell lymphoma. Blood 102:2638–2641CrossRefPubMed

16.

Facer CA, Playfair JH (1989) Malaria, Epstein-Barr virus, and the genesis of lymphomas. Adv Cancer Res 53:33–72CrossRefPubMed

17.

Ferreri AJ, Dognini GP, Campo E, Willemze R, Seymour JF, Bairey O, Martelli M, De Renz AO, Doglioni C, Montalban C, Tedeschi A, Pavlovsky A, Morgan S, Uziel L, Ferracci M, Ascani S, Gianelli U, Patriarca C, Facchetti F, Dalla LA, Pertoldi B, Horvath B, Szomor A, Zucca E, Cavalli F, Ponzoni M (2007) Variations in clinical presentation, frequency of hemophagocytosis and clinical behavior of intravascular lymphoma diagnosed in different geographical regions. Haematologica 92:486–492CrossRefPubMed

18.

Gascoyne RD, Campo E, Jaffe ES, Chan WC, Chan JKC, Rosenwald A, Stein H, Swerdlow SH (2018) Diffuse large B-cell lymphoma, NOS in WHO classification of tumours of haematopoietic and lymphoid tissues. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R (Hrsg) IARC, Lyon, S 291–297

19.

Ghosh SK, Wood C, Boise LH, Mian AM, Deyev VV, Feuer G, Toomey NL, Shank NC, Cabral L, Barber GN, Harrington WJ (2003) Potentiation of TRAIL-induced apoptosis in primary effusion lymphoma through azidothymidine-mediated inhibition of NF-kappa B. Blood 101:2321–2327CrossRefPubMed

20.

Griner LAM, Guha R, Shinn P, Young RM, Keller JM, Liu D, Goldlust IS, Yasgar A, McKnight C, Boxer MB, Duveau DY, Jiang J-K, Michael S, Mierzwa T, Huang W, Walsh MJ, Mott BT, Patel P, Leister W, Maloney DJ, Leclair CA, Rai G, Jadhav A, Peyser BD, Austin CA, Martin SE, Simeonov A, Ferrer M, Staudt LM, Thomas CJ (2014) High-throughput combinatorial screening identifies drugs that cooperate with irubtinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. PNAS 111:2349–2354CrossRef

21.

Gutierrez-Garcia G, Cardesa-Salzmann T, Climent F, Gonzalez-Barca E, Mercadal S, Mate JL, Sancho JM, Arenillas L, Serrano S, Escoda L, Martinez S, Valera A, Martinez A, Jares P, Pinyol M, Garcia-Herrera A, Martinez-Trillos A, Gine E, Villamor N, Campo E, Colomo L, Lopez-Guillermo A (2011) Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large-B-cell lymphoma treated with immunochemotherapy. Blood 117:4836–4843CrossRefPubMed

22.

Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275–282CrossRefPubMed

23.

Hartmann S, Döring C, Vucic E, Chan FC, Ennishi D, Tousseyn T, de Wolf-Peeters C, Perner S, Wlodarska I, Steidl C, Gascoyne RD, Hansmann ML (2015) Array comparative genomic hybridization reveals similarities between nodular lymphocyte predominant Hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma. Br J Haematol 169:415–422CrossRefPubMed

24.

Hong JY, Yoon DH, Suh C, Huh J, Do IG, Sohn I, Jo J, Jung SH, Hong ME, Yoon H, Ko YH, Kim SJ, Kim WS (2015) EBV-positive diffuse large B-cell lymphoma in young adults: is this a distinct disease entity? Ann Oncol 26:548–555CrossRefPubMed

25.

Hongyo T, Kurooka M, Taniguchi E, Iuchi K, Nakajima Y, Aozasa K, Nomura T (1998) Frequent p53 mutations at dipyrimidine sites in patients with pyothorax-associated lymphoma. Cancer Res 58:1105–1107PubMed

26.

Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC, Klapper W, Hummel M, Stein H, Hansmann ML, Schmelter C, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Siebert R, Loeffler M, Rosenwald A, Ott G (2013) MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 121:2253–2263CrossRefPubMed

27.

Horn H, Staiger AM, Vöhringer M, Hay U, Campo E, Rosenwald A, Ott G, Ott MM (2015) Diffuse large B-cell lymphomas of immunoblastic type are major reservoir for MYC-IGH translocations. Am J Surg Pathol 39:61–66CrossRefPubMed

28.

Hummel M, Agnastopoulos I, Korbjuhn P, Stein H (1995) Epstein-Barr-Virus in B-cell non-Hodgkin’s lymphomas: unexpected infection patterns and different infection incidence in low- and high-grade types. JPathol 175:263–271CrossRefPubMed

29.

Hummel M, Bentink S, Berger H, Klapper W, Wessendorf S, Barth TF, Bernd HW, Cogliatti SB, Dierlamm J, Feller AC, Hansmann ML, Haralambieva E, Harder L, Hasenclever D, Kühn M, Lenze D, Lichter P, Martin-Subero JI, Möller P, Müller-Hermelink HK, Ott G, Parwaresch RM, Pott C, Rosenwald A, Rosolowski M, Schwaenen C, Stürzenhofecker B, Szczepanowski M, Trautmann H, Wacker HH, Spang R, Loeffler M, Trümper L, Stein H, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe (2006) A biologic definition of Burkitt’s lymphoma from transcriptional and genomic profiling. N Engl J Med 354:2419–2430CrossRefPubMed

30.

Johnson NA, Savage KJ, Ludkovski O, Ben-Neriah S, Woods R, Steidl C, Dyer MJ, Siebert R, Kuruvilla J, Klasa R, Connors JM, Gascoyne RD, Horsman DE (2009) Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood 114:2273–2279CrossRefPubMedPubMedCentral

31.

Klein U, Gloghini A, Gaidano G, Chadburn A, Cesarman E, Dalla-Favera R, Carbone A (2003) Gene expression profile analysis of AIDS-related primary effusion lymphoma (PEL) suggests a plasmablastic deriviation and identifies PEL-specific transcripts. Blood 101:4115–4121CrossRefPubMed

32.

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M, Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle A, May L, Gascoyne RD, Connors JM, Troen G, Holte H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI, Hartmann E, Rosenwald A, Ott G, Muller-Hermelink HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan WC, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project (2008) Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 359(22):2313–2323CrossRefPubMedPubMedCentral

33.

Li S, Seegmiller AC, Lin P, Wang XJ, Miranda RN, Bhagavathi S, Medeiros LJ (2015) B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas. Mod Pathol 28:208–217CrossRefPubMed

34.

Lin P, Dickason TJ, Fayad LE, Lennon PA, Hu P, Garcia M, Routbort MJ, Miranda R, Wang X, Qiao W, Medeiros LJ (2012) Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma. Cancer 118:1566–1573CrossRefPubMed

35.

Macon WR, Cousar JB, Waldron JA Jr, Hsu SM (1992) Interleukin-4 may contribute to the abundant T-cell reaction and paucity of neoplastic B cells in T-cell rich B-cell lymphomas. Am J Pathol 141:1031–1036PubMedPubMedCentral

36.

Martin A, Capron F, Liguory-Brunaud MD, De Frejaques C, Pluot M, Diebold J (1994) Epstein-Barr virus-associated primary malignant lymphoma of the pleural cavity occurring in longstanding pleural chronic inflammation. Hum Pathol 25:1314–1318CrossRefPubMed

37.

Momose S, Weissbach S, Pischimarov J, Nedeva T, Bach E, Rudelius M, Geissinger E, Staiger AM, Ott G, Rosenwald A (2015) The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum. Leukemia 29(8):1789–1791CrossRefPubMed

38.

Morscio J, Dierickx D, Nijs J, Verhoef G, Bittoun E, Vanoeteren X, Wlodarska I, Sagaert X, Tousseyn T (2014) Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol 38:875–886CrossRefPubMed

39.

Nador RG, Cesarman E, Chadburn A, Dawson DB, Ansari MQ, Sald J, Knowles DM (1996) Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi’s sarcoma-associated herpes virus. Blood 88:645–656PubMed

40.

Nakatsuka S, Yao M, Hoshida Y, Yamamoto S, Iuchi K, Aozasa K (2002) Pyothorax-associated lymphoma: a review of 106 cases. J Clin Oncol 20:4255–4260CrossRefPubMed

41.

Narimatsu H, Ota Y, Kami M, Takeuchi K, Suzuki R, Matsuo K, Matsumura T, Yuji K, Kishi Y, Hamaki T, Sawada U, Miyata S, Sasaki T, Tobinai K, Kawabata M, Atsuta Y, Tanaka Y, Ueda R, Nakamura S (2007) Clinicopathological features of pyothorax-associated lymphoma; a retrospective survey involving 98 patients. Ann Oncol 18:122–128CrossRefPubMed

42.

Nicolae A, Pittaluga S, Abdullah S, Steinberg SM, Pham TA, Davies-Hill T, Xi L, Raffeld M, Jaffe ES (2015) EBV-positive large B-cell lymphomas in young patients: a nodal lymphoma with evidence for a tolerogenic immune environment. Blood 126(7):863–872CrossRefPubMedPubMedCentral

43.

Offit K, Lo CF, Louie DC, Parsa NZ, Leung D, Portlock C, Ye BH, Lista F, Filippa DA, Rosenbaum A (1994) Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 331:74–80CrossRefPubMed

44.

Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, Thorns C, Feller AC, Lenze D, Hummel M, Stein H, Müller-Hermelink HK, Frank M, Hansmann ML, Barth TF, Möller P, Cogliatti S, Pfreundschuh M, Schmitz N, Trümper L, Loeffler M, Rosenwald A (2010) Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 116:4916–4925CrossRefPubMed

45.

Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y, Yokoi T, Kojima M, Kamiya Y, Taji H, Kagami Y, Ogura M, Saito H, Morishima Y, Nakamura S (2003) Senile EBV+ B-cell lymphoproliferative disorders: a clinicopathologic study of 22 patients. Am J Surg Pathol 27:16–26CrossRefPubMed

46.

Oyama T, Yamamoto K, Asano N, Oshiro A, Suzuki R, Kagami Y, Morishima Y, Takeuchi K, Izumo T, Mori S, Oshima K, Suzumiya J, Nakamura N, Abe M, Ichimnura K, Sato Y, Yoshino T, Naoe T, Shimoyama Y, Kamiya K, Kinoshita T, Nakamura S (2007) Age-related EBV-associated B-cell lymphoproliferative disorders constitute a distinct clinicopathologic group: a study of 96 patients. Clin Cancer Res 13:5124–5132CrossRefPubMed

47.

Pedersen MØ, Gang AO, Poulsen TS, Knudsen H, Lauritzen AF, Nielsen SL, Klausen TW, Nørgaard P (2014) MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations. Eur J Haematol 92:42–48CrossRefPubMed

48.

Perry AM, Crockett D, Dave BJ, Althof P, Winkler L, Smith LM, Aoun P, Chan WC, Fu K, Greiner TC, Bierman P, Bociek GR, Vose JM, Armitage JO, Weisenburger DD (2013) B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases. Br J Haematol 162:40–49CrossRefPubMed

49.

Ponzoni M, Arrigoni G, Gould VE, Del Curto B, Maggioni M, Scapinello A, Paolino S, Cassisa A, Patriaca C (2000) Lack of CD29 (beta 1 integrin) and CD54 (ICAM-1) adhesion molecules in intravascular lymphomatosis. Hum Pathol 31:220–226CrossRefPubMed

50.

Raphael M, Gentilhomme O, Tulliez M, Byron PA, Diebold J (1991) Histopathologic features of high-grade non-Hodgkin’s lymphomas in acquired immunodeficiency syndrome. The French Study Group of Pathology for Human Immunodeficiency Virus-Associated Tumors. Arch Pathol Lab Med 115:15–20PubMed

51.

Reichard KK, McKenna RW, Kroft SH (2007) ALK-positive diffuse large B-cell lymphoma: report of four cases and review of the literature. Mod Pathol 20:310–319CrossRefPubMed

52.

Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, Lenze D, Szczepanowski M, Paulsen M, Lipinski S, Russell RB, Adam-Klages S, Apic G, Claviez A, Hasenclever D, Hovestadt V, Hornig N, Korbel JO, Kube D, Langenberger D, Lawerenz C, Lisfeld J, Meyer K, Picelli S, Pischimarov J, Radlwimmer B, Rausch T, Rohde M, Schilhabel M, Scholtysik R, Spang R, Trautmann H, Zenz T, Borkhardt A, Drexler HG, Möller P, MacLeod RA, Pott C, Schreiber S, Trümper L, Loeffler M, Stadler PF, Lichter P, Eils R, Küppers R, Hummel M, Klapper W, Rosenstiel P, Rosenwald A, Brors B, Siebert R, MMML-Seq Project ICGC (2012) Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 44:1316–1320CrossRefPubMed

53.

Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275–282CrossRefPubMed

54.

Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher R, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage JQ, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, Kvaloy S, DelabieJ, Holte H, Krajci P, Stokke T, Staudt LM, Lymphoma/Leukemia Molecular Profiling Project (2002) The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937–1947CrossRefPubMed

55.

Salaverria I, Philipp C, Oschlies I, Kohler CW, Kreuz M, Szczepanowski M, Burkhardt B, Trautmann H, Gesk S, Andrusiewicz M, Berger H, Fey M, Harder L, Hasenclever D, Hummel M, Loeffler M, Mahn F, Martin-Guerrero I, Pellissery S, Pott C, Pfreundschuh M, Reiter A, Richter J, Rosolowski M, Schwaenen C, Stein H, Trümper L, Wessendorf S, Spang R, Küppers R, Klapper W, Siebert R, Molecular Mechanisms in Malignant Lymphomas Network Project of the Deutsche Krebshilfe, German High-Grade Lymphoma Study Group, Berlin-Frankfurt-Münster-NHL trial group (2011) Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults. Blood 118:139–147CrossRefPubMed

56.

Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, Xu W, Zhao H, Kohlhammer H, Rosenwald A, Kluin P, Müller-Hermelink HK, Ott G, Gascoyne RD, Connors JM, Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB, Ogwang MD, Reynolds SJ, Fisher RI, Braziel RM, Tubbs RR, Cook JR, Weisenburger DD, Chan WC, Pittaluga S, Wilson W, Waldmann TA, Rowe M, Mbulaiteye SM, Rickinson AB, Staudt LM (2012) Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 490(7418):116–120CrossRefPubMedPubMedCentral

57.

Scott DW, King RL, Staiger AM, Ben-Neriah S, Jiang A, Horn H, Mottok A, Farinha P, Slack GW, Ennishi D, Schmitz N, Pfreundschuh M, Nowakowski GS, Kahl BS, Connors JM, Gascoyne RD, Ott G, Macon WR, Rosenwald A (2018) High grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood :12–820605

58.

Scott DW, Wright GW, Williams PM, Lih C-J, Walsh W, Jaffe ES, Rosenwald A, Campo E, Chan WC, Connors JM, Smeland EB, Mottok A, Braziel RM, Ott G, Delabie J, Tubbs RR, Cook JR, Weisenburger DD, Greiner TG, Glinsmann-Gibson BJ, Fu K, Staudt LM, Gascoyne RD, Rimsza LM (2014) Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood 123:1214–1217CrossRefPubMedPubMedCentral

59.

Slack GW, Gascoyne RD (2011) MYC and aggressive B-cell lymphomas. Adv Anat Pathol 18:219–228CrossRefPubMed

60.

Snuderl M, Kolman OK, Chen YB, Hsu JJ, Ackerman AM, Dal Cin P, Ferry JA, Harris NL, Hasserjian RP, Zukerberg LR, Abramson JS, Hochberg EP, Lee H, Lee AI, Toomey CE, Sohani AR (2010) B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. Am J Surg Pathol 34:327–340CrossRefPubMedPubMedCentral

61.

Swerdlow SH (2014) Diagnosis of ’double hit’ diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC. Hematology Am Soc Hematol Educ Program 1:90–96CrossRef

62.

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri S, Stein H, Thiele J, Arber DA, Hasserjian RP, Le Beau MM, Orazi A, Siebert R (Hrsg) (2018) WHO classification of tumors of haematopoietic and lymphoid tissues. IARC, Lyon

63.

Valera A, Balague O, Colomo L, Martinez A, Delabie J, Taddesse-Heath L, Jaffe ES, Campo E (2010) IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol 34:1686–1694PubMedPubMedCentral

64.

Valera A, Colomo L, Martinez A, de Jong D, Balague O, Matheu G, Martinez M, Tadesse-Heath L, Jaffe ES, Bacchi CE, Campo E (2013) ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Mod Pathol 26:1329–1337CrossRefPubMedPubMedCentral

65.

Wagener E, Alexandrov LB, Montesinos-Rongen M, Schlesner M, Haake A, Drexler HG, Richter J, Bignell GR, McDermott U, Siebert R (2015) Analysis of mutational signatures in exomes from B-cell lymphoma cell lines suggest APOBEC3 family members to be involved in the pathogenesis of primary effusion lymphoma. Leukemia 29:1612–1615CrossRefPubMed

66.

Weiss LM, Warnke RA, Sklar J, Cleary ML (1987) Molecular analysis of the t(14;18) chromosomal translocation in malignant lymphomas. N Engl J Med 317:1185–1189CrossRefPubMed

67.

Wright G, Tan B, Rosenwald A, Hurt EH, Wiestner A, Staudt LM (2003) A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B-cell lymphoma. Proc Natl Acad Sci Usa 100:9991–9996CrossRefPubMedPubMedCentral

68.

Yeh YM, Chang KC, Chen YP, Kao LY, Tsai HP, Ho CL, Wang JR, Jones D, Chen TY (2010) Large B cell lymphoma presenting initially in bone marrow, liver and spleen: an aggressive entity associated frequently with haemophagocytic syndrome. Histopathology 57:785–795CrossRefPubMed

Titel: Großzellige und aggressive B-Zell Lymphome
verfasst von: Prof. Dr. Andreas Rosenwald
Prof. Dr. Martina Rudelius
Verlag: Springer Berlin Heidelberg
Buch: Pathologie
Print ISBN: 978-3-540-85183-7

Electronic ISBN: 978-3-540-85184-4

Copyright-Jahr: 2019
DOI: https://doi.org/10.1007/978-3-540-85184-4_23

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

23. Großzellige und aggressive B-Zell Lymphome

Zusammenfassung

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Neu im Fachgebiet Pathologie

Molekularpathologische Untersuchungen im Wandel der Zeit

Vergleichende Pathologie in der onkologischen Forschung

Gastrointestinale Stromatumoren

Personalisierte Medizin in der Onkologie